The effect of pramipexole on mood and motivational symptoms in parkinson's disease: A meta-analysis of placebo-controlled studies

2000 Reijnders, 2008, A systematic review of prevalence studies of depression in Parkinson's disease, Mov Disord, 23, 183, 10.1002/mds.21803 Hobson, 1999, Measuring the impact of Parkinson's Disease Quality of Life questionnaire, Age Ageing, 28, 341, 10.1093/ageing/28.4.341 Liu, 1997, The correlation of depression with functional activity in Parkinson's disease, J Neurol, 244, 493, 10.1007/s004150050131 Aarsland, 1999, Range of neuropsychiatrie disturbances in patients with Parkinson's disease, J Neurol Neurosurg Psychiatry, 67, 492, 10.1136/jnnp.67.4.492 Troster, 1995, Neuropsychological impairment in Parkinson's disease with and without depression, Arch Neurol, 52, 1164, 10.1001/archneur.1995.00540360042014 Weintraub, 2004, Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease, J Am Ceriatr Soc, 52, 784, 10.1111/j.1532-5415.2004.52219.x Kirsch-Darrow, 2006, Dissociating apathy and depression in Parkinson's disease, Neurology, 67, 1315, 10.1212/01.wnl.0000230572.07791.22 Kirsch-Darrow, 2006, Dissociating apathy and depression in Parkinson's disease, Neurology, 67, 33, 10.1212/01.wnl.0000230572.07791.22 Starkstein, 1992, Reliability, validity, and clinical correlates of apathy in Parkinson's disease, J Neuropsych Clin Neurosci, 4, 134, 10.1176/jnp.4.2.134 Piercey, 1998, Pharmacology of prami-pexole, a dopamine D3-prefernng agonist useful in treating Parkinson's disease, Clin Neuropharmacol, 21, 141 Basso, 2005, Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test, Neuropsychopharmacology, 30, 1257, 10.1038/sj.npp.1300677 Dikeos, 1999, Association between the dopamine D3 receptor gene locus (DRD3) and unipolar affective disorder, Psychiatr Genet, 9, 189, 10.1097/00041444-199912000-00005 Lemke, 2005, Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole, J Neuropsychiatry Clin Neurosci, 17, 214, 10.1176/appi.neuropsych.17.2.214 Reichmann, 2003, Pramipexole in routine clinical practice: A prospective observational trial in Parkinson's disease, CNS Drugs, 17, 965, 10.2165/00023210-200317130-00003 Rektorová, 2003, Pramipexole and pergohde in the treatment of depression in Parkinson's disease: A national multicentre prospective randomized study, Eur J Neurol, 10, 399, 10.1046/j.1468-1331.2003.00612.x Barone, 2006, Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multi-center parallel-group randomized study, J Neurol, 235, 601, 10.1007/s00415-006-0067-5 Fahn, 1987, Unified Parkinson's Disease Rating Scale, 153 Lieberman, 1997, Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study, Neurology, 49, 162, 10.1212/WNL.49.1.162 Pinter, 1999, Efficacy, safety, and tolerance of the non-ergohne dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study, J Neurol Neu rosu rg Psychiatry, 66, 436, 10.1136/jnnp.66.4.436 Wermuth, 1998, A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease, Eur J Neurol, 5, 235, 10.1046/j.1468-1331.1998.530235.x Guttman, 1997, Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease, Neurology, 49, 1060, 10.1212/WNL.49.4.1060 1997, Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study, JAMA, 278, 125, 10.1001/jama.278.2.125 Moller, 2005, Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial, Mov Disord, 20, 602, 10.1002/mds.20397 Wemtraub, 2005, Antidepressant studies in Parkinson's disease: A review and meta-analysis, Mov Disord, 20, 1161, 10.1002/mds.20555 Navan, 2003, Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergohde, and placebo on Parkinsonian tremor, Mov Disord, 18, 1324, 10.1002/mds.10538 Fibiger, 1984, The neurobiological substrates of depression in Parkinson's disease: A hypothesis, Can J Neurol Sci, 11, 105, 10.1017/S0317167100046230 Lieberman, 2006, Depression in Parkinson's disease-a review, Acta Neurol Scand, 113, 1, 10.1111/j.1600-0404.2006.00536.x Pahwa, 2007, Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease, Neurology, 68, 1108, 10.1212/01.wnl.0000258660.74391.c1 Buchwald, 2007, Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy [in German], Fortschr Neurol Psychiatr, 75, 236, 10.1055/s-2007-959188 Schrag, 2007, Depression rating scales in Parkinson's disease: Critique and recommendations, Mov Disord, 22, 1077, 10.1002/mds.21333 Leentjens, 2008, Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations, Mov Disord, 23, 2004, 10.1002/mds.22229 Louis, 1996, Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale, Mov Disord, 11, 185192, 10.1002/mds.870110212 Martinez-Martín, 1994, Unified Parkinson's Disease Rating Scale characteristics and structure, Mov Disord, 9, 76, 10.1002/mds.870090112